EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor

被引:57
作者
Li, J-J [2 ]
Liu, D-P
Liu, G-T [3 ]
Xie, D. [1 ]
机构
[1] Chinese Acad Sci, Mol Oncol Lab, Inst Nutr Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China
[2] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
基金
中国国家自然科学基金;
关键词
ephrinA5; EGFR; c-Cbl; glioma; C-CBL; EPH RECEPTORS; TYROSINE KINASES; GENE-EXPRESSION; CANCER CELLS; T-CELLS; PHOSPHORYLATION; BINDING; LIGAND; TUMORIGENICITY;
D O I
10.1038/onc.2009.15
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Eph receptors, the largest subfamily of receptor tyrosine kinases, and their ephrin ligands play important roles in nervous system development. Recently, they have been implicated in tumorigenesis of different cancers. In this study, we showed that the expression of ephrinA5 was dramatically downregulated in primary gliomas compared with normal tissues. Forced expression of ephrinA5 reduced tumorigenicity of human glioma U373 cells. Epidermal growth factor receptor (EGFR), which frequently acts as an oncoprotein in glioma, was greatly decreased in ephrinA5-transfected glioma cells, and the two molecules exhibited a mutually exclusive expression pattern in primary glioma samples. We found that ephrinA5 enhanced c-Cbl binding to EGFR, thus promoted ubiquitylation and degradation of the receptor. Either ephrinA5-Fc or EphA2-Fc treatment simulating bidirectional signaling of Eph/ephrin system resulted in EGFR decrease. This study discovered that ephrinA5 acted as a tumor suppressor in glioma, and its negative regulation of EGFR contributed to the suppressive effects. In addition to identifying a novel mechanism underlying tumor suppressor activity of ephrinA5, we also showed cross-talk between different receptor tyrosine kinase families in glioma. These.ndings may improve therapeutic strategies for glioma.
引用
收藏
页码:1759 / 1768
页数:10
相关论文
共 36 条
[1]   Multiple roles of ephrins during the formation of thalamocortical projections:: Maps and more [J].
Bolz, J ;
Uziel, D ;
Mühlfriedel, S ;
Güllmar, A ;
Peuckert, C ;
Zarbalis, K ;
Wurst, W ;
Torii, M ;
Levitt, P .
JOURNAL OF NEUROBIOLOGY, 2004, 59 (01) :82-94
[2]  
BORDIER C, 1981, J BIOL CHEM, V256, P1604
[3]   Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice [J].
Brantley-Sieders, Dana M. ;
Fang, Wei Bin ;
Hwang, Yoonha ;
Hicks, Donna ;
Chen, Jin .
CANCER RESEARCH, 2006, 66 (21) :10315-10324
[4]   Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion [J].
Davy, A ;
Gale, NW ;
Murray, EW ;
Klinghoffer, RA ;
Soriano, P ;
Feuerstein, C ;
Robbins, SM .
GENES & DEVELOPMENT, 1999, 13 (23) :3125-3135
[5]   Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through β-catenin-T-cell factor/Lef signaling [J].
Deng, Yue-Zhen ;
Chen, Ping-Ping ;
Wang, Yan ;
Yin, Dong ;
Koeffler, H. Phillip ;
Li, Baojie ;
Tong, Xiang-Jun ;
Xie, Dong .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (50) :36571-36581
[6]   A new ephrin-A1 isoform (ephrin-A1b) with altered receptor binding properties abrogates the cleavage of ephrin-A1a [J].
Finne, EF ;
Munthe, E ;
Aasheim, HC .
BIOCHEMICAL JOURNAL, 2004, 379 :39-46
[7]   Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis [J].
Gale, NW ;
Holland, SJ ;
Valenzuela, DM ;
Flenniken, A ;
Pan, L ;
Ryan, TE ;
Henkemeyer, M ;
Strebhardt, K ;
Hirai, H ;
Wilkinson, DG ;
Pawson, T ;
Davis, S ;
Yancopoulos, GD .
NEURON, 1996, 17 (01) :9-19
[8]   Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl [J].
Grossmann, AH ;
Kolibaba, KS ;
Willis, SG ;
Corbin, AS ;
Langdon, WS ;
Deininger, MWN ;
Druker, BJ .
FEBS LETTERS, 2004, 577 (03) :555-562
[9]   Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers [J].
Hafner, C ;
Schmitz, G ;
Meyer, S ;
Bataille, F ;
Hau, P ;
Langmann, T ;
Dietmaier, W ;
Landthaler, M ;
Vogt, T .
CLINICAL CHEMISTRY, 2004, 50 (03) :490-499
[10]   Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours [J].
Halatsch, ME ;
Schmidt, U ;
Behnke-Mursch, J ;
Unterberg, A ;
Wirtz, CR .
CANCER TREATMENT REVIEWS, 2006, 32 (02) :74-89